This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Frohlich, E. D. Articles by Ré, R. N. Search for Related Content PubMed PubMed Citation Articles by Frohlich, E. D. Articles by Ré, R. N.

(Hypertension. 1999;34:371.)
© 1999 American Heart Association, Inc.

Editorial

Council Honorees and the Nobel Prize

Our Continued Anniversary Celebration

Edward D. Frohlich, MD, Editor-in-Chief
L. Gabriel Navar, PhD
Richard N. Ré, MD, Associate Editors

	Introduction

 
In the continuing celebration of the 20th anniversary of Hypertension, we are once again pleased to salute those special honorees and lecturers of the Council for High Blood Pressure Research (CHBPR) who later received the Nobel Prize for their seminal research. Each of these individuals either had been selected as a recipient of the Stouffer, Ciba, or Novartis Award or was a featured speaker invited to present the Corcoran or other important special lectures. Sometime after being acknowledged by the Council, they were selected to receive the Nobel Prize in Medicine for their outstanding work.

In this month's issue, we honor Sir James W. Black. It was in 1976 that Sir James Black (then head of biological research at Smith Kline & French Laboratories) received the Ciba Award at the Council for High Blood Pressure Research meeting. Dr Raymond P. Ahlquisht, PhD, also received the Ciba Award that year for his exposition of the concept of alpha- and beta-adrenergic receptor sites; and, Sir James Black was recognized for the development of beta-adrenergic receptor antagonists. It was later, in 1988, that Sir James Black and Doctors Gertrude B. Elion and George H. Hitchings were jointly honored with the Nobel Prize for their annunciation of the fundamental concept of the physiological receptor site, leading to the development of specific receptor-blocking pharmacological agents that inhibit those naturally occurring physiological receptor sites. Sir James Black, now at the King's College Hospital Medical School in London, developed two important drugs at that time: propanolol, . . . [Full Text of this Article]